Skip to main content

Who We Are
Our Science
Careers
Investors
News

Home
Stock Info
Events & Presentations
Financial Documents
Press Releases
Leadership
Governance
Investor Info

Price

Change

Volume

As of Dec 21, 2024 5:42 AM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events & Presentations

Corporate Presentation

Zymeworks Corporate Deck 3.8 MB

Upcoming Events

43rd Annual J.P. Morgan Healthcare Conference

Jan 16, 2025 8:15 AM PST

Location

San Francisco

Add to Google Calendar

Past Events

Jefferies Virtual Healthcare Conference

Jun 3, 2021

Zymeworks' Annual General Meeting

May 5, 2021

Listen to webcast

Bloom Burton Healthcare Investor Conference

Apr 20, 2021

American Association for Cancer Research (AACR) Annual Meeting

Apr 10, 2021

Title: Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action 4.3 MB

Title: The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers 4.3 MB

Title: ProTECT™, a novel antibody platform for integrating tumor-specific immune modulation and enhancing the therapeutic window of targeted multispecific biologics 9.3 MB

Title: Increasing the therapeutic index of IL-12 by engineering for tumor-specific protease activation 2.7 MB

Title: Understanding the geometry and valency of bispecific antibodies in the optimization of tumor-dependent activation of 4-1BB 5.2 MB

Barclays Global Healthcare Conference

Mar 11, 2021

ZW49 Clinical Update Conference Call

Jan 27, 2021

Listen to webcast

Zanidatamab ASCO GI Conference Call

Jan 15, 2021

Presentation 15.6 MB

American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

Jan 15, 2021

Title: A Phase 2b, Open-label, Single-arm Study of Zanidatamab (ZW25) Monotherapy in Patients with Advanced or Metastatic HER2-amplified Biliary Tract Cancer (BTC): HERIZON-BTC-01 Study 410.1 KB

Title: Zanidatamab (ZW25) in HER2-positive Biliary Tract Cancer (BTC): Results From a Phase 1 Study 390.9 KB

Title: Zanidatamab (ZW25) in HER2-expressing Gastroesophageal Adenocarcinoma (GEA): Results from a Phase 1 Study 1.8 MB

JP Morgan Healthcare Conference

Jan 11, 2021

Wolfe’s 2020 Virtual Healthcare Conference

Nov 19, 2020

First page
Previous page
…
Page 8
Page 9
Current page 10
Page 11
Next page
Last page

Who We Are

About Us
Leadership
Board of Directors
Partners

Our Science

About Our Science
Our Technology
Our Pipeline

Patients

Our Patients
Clinical Trials

Corporate

Careers
Terms of Use
Privacy Policy
Contact

© 2024, Zymeworks Inc.